Ovagen

Overview

Ovagen is a Khavinson bioregulator tripeptide (EDL) with primary effects on the liver and gastrointestinal tract. Developed by Dr. Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it reduces long-term liver fibrosis and protects the GI mucosal layer from antibiotics, environmental toxins, and chemotherapy. Like other bioregulators, Ovagen crosses cell and nuclear membranes to directly regulate DNA transcription patterns with tissue-specific effects.

Mechanism of action

Ovagen works through epigenetic regulation by crossing cell and nuclear membranes to directly regulate DNA structure and transcription patterns. It is transported into cells via POT family transporters (PEPT1, PEPT2) that specifically handle di- and tripeptides, explaining its precise tissue targeting. The peptide has tissue-specific effects on liver and GI tract, reducing fibrosis and protecting mucosal integrity.

Key research findings

• Reduces long-term liver fibrosis
• Protects GI mucosal layer
• Defense against antibiotic damage
• Protection from environmental toxins
• May protect against chemotherapy GI effects
• Tissue-specific targeting via PEPT transporters
• Direct DNA regulation
• Part of comprehensive anti-aging protocols

Research applications

Liver Support

• Liver Fibrosis — Reduces long-term fibrosis development in liver tissue.
• Hepatoprotection — Protects liver through gene expression regulation.

GI Protection

• Mucosal Protection — Helps protect GI mucosal layer from various insults.
• Antibiotic Recovery — May protect GI tract from antibiotic-induced damage.
• Toxin Defense — Protects against environmental toxin effects on GI tract.

Anti-Aging

• Liver Aging — Addresses age-related liver changes through bioregulation.
• GI Aging — Supports GI tract function during aging.